Diagnostic Tools in the Indications for Allogeneic Stem Cell Transplantation in Myelodysplastic Syndromes

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages 1-11

  Bacher, Ulrike ^a   Haferlach, Claudia ^b   Kröger, Nicolaus ^a   Schnittger, Susanne ^a   Kern, Wolfgang ^a   Wiedemann, Bettina ^a   Zander, Axel Rolf ^a   Haferlach, Torsten ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Allogeneic stem cell transplantation; Cytogenetics; International Prognostic Scoring System; Myelodysplastic syndrome; Risk stratification; World Health Organization classification

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOSPORIN; DNA TOPOISOMERASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALGORITHM; ALLOGENEIC STEM CELL TRANSPLANTATION; ANALYTIC METHOD; CELL STRUCTURE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BANDING PATTERN; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CYTOGENETICS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FRENCH AMERICAN BRITISH SYSTEM; GENE EXPRESSION; GENETIC SCREENING; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REVIEW; RISK ASSESSMENT; STANDARDIZATION; SURVIVAL TIME; TREATMENT INDICATION; WORLD HEALTH ORGANIZATION;

CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DNA MUTATIONAL ANALYSIS; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; WORLD HEALTH ORGANIZATION;

EID: 72649096494     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.08.007     Document Type: Review

References (111)

1. Cazzola M., and Malcovati L. Myelodysplastic syndromes: coping with ineffective hematopoiesis. N Engl J Med 352 (2005) 536-538
2. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
3. Mufti G.J., and Chen T.L. Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control 15 Suppl (2008) 14-28
4. Hofmann W.K., Heil G., Zander C., et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 83 (2004) 498-503
5. Beran M. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Int J Hematol 72 (2000) 139-150
6. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 1456-1465
7. Gratwohl A., Schmid O., Baldomero H., et al. Haematopoietic stem cell transplantation (HSCT) in Europe 2002: changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplant 34 (2004) 855-875
8. Deeg H.J., Shulman H.M., Anderson J.E., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95 (2000) 1188-1194
9. Kroger N., Bornhauser M., Ehninger G., et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 82 (2003) 336-342
10. Alyea E.P., Kim H.T., Ho V., et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 12 (2006) 1047-1055
11. Deeg H.J. Transplant strategies for patients with myelodysplastic syndromes. Curr Opin Hematol 13 (2006) 61-66
12. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579-585
13. De Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110 (2000) 620-630
14. Oliansky D.M., Antin J.H., Bennett J.M., et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant 15 (2009) 137-172
15. Itzykson R., and Fenaux P. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Curr Opin Hematol 16 (2009) 77-83
16. Cermak J., Michalova K., Brezinova J., et al. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome. Leuk Res 27 (2003) 221-229
17. Goasguen J.E. Is it still possible to ameliorate the diagnosis of refractory anemia?. Leuk Res 27 (2003) 201-203
18. Wells D.A., Benesch M., Loken M.R., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 102 (2003) 394-403
19. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088
20. Haase D., Germing U., Schanz J., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110 (2007) 4385-4395
21. Stewart B., Verdugo M., Guthrie K.A., et al. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. Br J Haematol 123 (2003) 879-885
22. Pozdnyakova O., Miron P.M., Tang G., et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 113 (2008) 3331-3340
23. Raj K., and Mufti G.J. Azacytidine (Vidaza) in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2 (2006) 377-388
24. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 360 (2009) 2289-2301
25. Langemeijer S.M., Kuiper R.P., Berends M., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41 (2009) 838-842
26. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
27. Swerdlow S., Campo E., Lee Harris N., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition (2008), WHO Press, Lyon, France
28. Germing U., Strupp C., Kuendgen A., et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91 (2006) 1596-1604
29. Breccia M., Mengarelli A., Mancini M., et al. Myelodysplastic syndromes in patients under 50 years old: a single-institution experience. Leuk Res 29 (2005) 749-754
30. Navarro I., Ruiz M.A., Cabello A., et al. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. Leuk Res 30 (2006) 971-977
31. Germing U., Strupp C., Kuendgen A., et al. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol 132 (2006) 162-167
32. Howe R.B., Porwit-MacDonald A., Wanat R., et al. The WHO classification of MDS does make a difference. Blood 103 (2004) 3265-3270
33. Bernasconi P., Boni M., Cavigliano P.M., et al. Clinical relevance of cytogenetics in myelodysplastic syndromes. Ann N Y Acad Sci 1089 (2006) 395-410
34. Valent P., Horny H.P., Bennett J.M., et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31 (2007) 727-736
35. Haferlach C., Rieder H., Lillington D.M., et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes. Genes Chromosomes Cancer 46 (2007) 494-499
36. Sole F., Luno E., Sanzo C., et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 90 (2005) 1168-1178
37. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 73 (2001) 429-437
38. Sole F., Espinet B., Sanz G.F., et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108 (2000) 346-356
39. Zou Y.S., Fink S.R., Stockero K.J., et al. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with lenalidomide. Leuk Res 31 (2007) 1185-1189
40. Giagounidis A.A., Germing U., Haase S., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18 (2004) 113-119
41. Cherian S., and Bagg A. The genetics of the myelodysplastic syndromes: classical cytogenetics and recent molecular insights. Hematology 11 (2006) 1-13
42. Giagounidis A.A., Germing U., Strupp C., et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 84 (2005) 569-571
43. Douet-Guilbert N., Basinko A., Morel F., et al. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions. Ann Hematol 87 (2008) 537-544
44. Bacher U. Schnittger S. Kern W. et al. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia-negative myeloproliferative neoplasms, and the overlap MDS/MPN category Ann Hematol In Press.
45. Brezinova J., Zemanova Z., Ransdorfova S., et al. Prognostic significance of del(20q) in patients with hematological malignancies. Cancer Genet Cytogenet 160 (2005) 188-192
46. Liu Y.C., Ito Y., Hsiao H.H., et al. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 171 (2006) 9-16
47. Douet-Guilbert N., Lai J.L., Basinko A., et al. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome. Br J Haematol 143 (2008) 716-720
48. Paulsson K., Sall T., Fioretos T., et al. The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. Cancer Genet Cytogenet 130 (2001) 160-165
49. Pedersen B. MDS and AML with trisomy 8 as the sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases. Am J Hematol 56 (1997) 224-229
50. De Souza F.T., Ornellas M.H., Otero de Carvalho L., et al. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res 24 (2000) 839-848
51. Bernasconi P., Klersy C., Boni M., et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 19 (2005) 1424-1431
52. Sole F., Torrabadella M., Granada I., et al. Isochromosome 17q as a sole anomaly: a distinct myelodysplastic syndrome entity?. Leuk Res 17 (1993) 717-720
53. Steensma D.P., and List A.F. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 80 (2005) 681-698
54. Smith S.M., Le Beau M.M., Huo D., et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102 (2003) 43-52
55. Armand P., Kim H.T., DeAngelo D.J., et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 13 (2007) 655-664
56. Herry A., Douet-Guilbert N., Morel F., et al. Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AML. Eur J Haematol 78 (2007) 457-467
57. Halling K.C., and Kipp B.R. Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol 38 (2007) 1137-1144
58. Shali W., Helias C., Fohrer C., et al. Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH. Cancer Genet Cytogenet 168 (2006) 133-145
59. Bigoni R., Cuneo A., Milani R., et al. Multilineage involvement in the 5q- syndrome: a fluorescent in situ hybridization study on bone marrow smears. Haematologica 86 (2001) 75-81
60. Lindvall C., Nordenskjold M., Porwit A., et al. Molecular cytogenetic characterization of acute myeloid leukemia and myelodysplastic syndromes with multiple chromosome rearrangements. Haematologica 86 (2001) 1158-1164
61. Babicka L., Ransdorfova S., Brezinova J., et al. Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH. Leuk Res 31 (2007) 39-47
62. Martinez-Ramirez A., Urioste M., Alvarez S., et al. Cytogenetic profile of myelodysplastic syndromes with complex karyotypes: an analysis using spectral karyotyping. Cancer Genet Cytogenet 153 (2004) 39-47
63. Barouk-Simonet E., Soenen-Cornu V., Roumier C., et al. Role of multiplex FISH in identifying chromosome involvement in myelodysplastic syndromes and acute myeloid leukemias with complex karyotypes: a report on 28 cases. Cancer Genet Cytogenet 157 (2005) 118-126
64. Trost D., Hildebrandt B., Beier M., et al. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia. Cancer. Genet Cytogenet 165 (2006) 51-63
65. Bernasconi P., Cavigliano P.M., Boni M., et al. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 17 (2003) 2107-2112
66. Panani A.D., and Pappa V. Hidden chromosome 8 abnormalities detected by FISH in adult primary myelodysplastic syndromes. In Vivo 19 (2005) 979-981
67. Trost D., Hildebrandt B., Muller N., et al. Hidden chromosomal aberrations are rare in primary myelodysplastic syndromes with evolution to acute myeloid leukaemia and normal cytogenetics. Leuk Res 28 (2004) 171-177
68. Rigolin G.M., Bigoni R., Milani R., et al. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 15 (2001) 1841-1847
69. Cherry A.M., Brockman S.R., Paternoster S.F., et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res 27 (2003) 1085-1090
70. Harada H., Harada Y., Niimi H., et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low-blast percentage myeloid leukemia with myelodysplasia. Blood 103 (2004) 2316-2324
71. Hellstrom-Lindberg E., Willman C., Barrett A.J., et al. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 1 (2000) 110-132
72. Dicker F, Haferlach C, Kern W, et al. Mutations in normal karyotype AML cooperate with class I mutations in the progression to s-AML following MDS. ASH Annual Meeting, 2008. Blood. 2008. 112, 924.
73. Schnittger S., Schoch C., Dugas M., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG Study and usefulness as a marker for the detection of minimal residual disease. Blood 100 (2002) 59-66
74. Yanada M., Matsuo K., Suzuki T., et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 19 (2005) 1345-1349
75. Shih L.Y., Huang C.F., Wang P.N., et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18 (2004) 466-475
76. Mitani K., Hangaishi A., Imamura N., et al. No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes. Leukemia 11 (1997) 863-865
77. Bacher U., Haferlach T., Kern W., et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 92 (2007) 744-752
78. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 (2005) 254-266
79. Zhang Y., Zhang M., Yang L., et al. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res 31 (2007) 109-111
80. Steensma D.P., Dewald G.W., Lasho T.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
81. Levine R.L., Loriaux M., Huntly B.J., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 106 (2005) 3377-3379
82. Szpurka H., Tiu R., Murugesan G., et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 108 (2006) 2173-2181
83. Miwa H., Beran M., and Saunders G.F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6 (1992) 405-409
84. Miyagi T., Ahuja H., Kubota T., et al. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 7 (1993) 970-977
85. Inoue K., Ogawa H., Sonoda Y., et al. Aberrant overexpression of the Wilms' tumor gene (WT1) in human leukemia. Blood 89 (1997) 1405-1412
86. Cilloni D., Gottardi E., De Micheli D., et al. Quantitative assessment of WT1 expression by real-time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16 (2002) 2115-2121
87. Cilloni D., and Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol 112 (2004) 79-84
88. Shimoni A., and Nagler A. Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced-intensity and nonmyeloablative conditioning. Acta Haematol 112 (2004) 93-104
89. Weisser M., Kern W., Rauhut S., et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19 (2005) 1416-1423
90. Bader P., Niemeyer C., Weber G., et al. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?. Eur J Haematol 73 (2004) 25-28
91. Tamaki H., Ogawa H., Ohyashiki K., et al. The Wilms' tumor gene, WT1, is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13 (1999) 393-399
92. Lorand-Metze I., Califani S.M., Ribeiro E., et al. The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leuk Res 32 (2008) 211-213
93. Stetler-Stevenson M., Arthur D.C., Jabbour N., et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 98 (2001) 979-987
94. Della Porta M.G., Malcovati L., Invernizzi R., et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 20 (2006) 549-555
95. Ogata K., Nakamura K., Yokose N., et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100 (2002) 3887-3896
96. Veltroni M., Sainati L., Zecca M., et al. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?. Pediatr Blood Cancer 52 (2009) 357-363
97. Truong F., Smith B.R., Stachurski D., et al. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study. Leuk Res 33 (2009) 1039-1046
98. Scott B.L., Wells D.A., Loken M.R., et al. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 112 (2008) 2681-2686
99. Van de Loosdrecht A., Alhan C., Bene M.C., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first ELNet working conference on flow cytometry in MDS. Haematologica 94 (2009) 1124-1134
100. Wang H., Chuhjo T., Yasue S., et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 100 (2002) 3897-3902
101. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 419-425
102. Armand P., Kim H.T., Cutler C.S., et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 14 (2008) 28-35
103. Bernasconi P., Klersy C., Boni M., et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol 137 (2007) 193-205
104. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25 (2007) 3503-3510
105. Cermak J., Vitek A., and Michalova K. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Leuk Res 28 (2004) 551-557
106. Tasaka T., Tohyama K., Kishimoto M., et al. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. Leukemia 22 (2008) 1874-1881
107. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 112 (2008) 895-902
108. Kindwall-Keller T., and Isola L.M. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant 43 (2009) 597-609
109. Kataoka K., Nannya Y., Hangaishi A., et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15 (2009) 195-204
110. Mills K.I., Kohlmann A., Williams P.M., et al. Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome (MDS). Blood 114 (2009) 1063-1072
111. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 87 (2008) 515-526